The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognosis and tumor-infiltrating lymphocytes (TILs) in estrogen receptor (ER)-low metastatic breast cancer (MBC): Analysis from a large multi-institutional cohort and the TONIC phase II trial with nivolumab.
 
Federica Miglietta
Consulting or Advisory Role - AstraZeneca; MSD
Speakers' Bureau - Gilead Sciences; Novartis; Pfizer; Seagen
Travel, Accommodations, Expenses - Gilead Sciences; Novartis
 
Claudio Vernieri
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Novartis; Pfizer
Speakers' Bureau - Accademia Nazionale Di Medicina (ACCMED); Istituto Gentili; Lilly; Novartis
Research Funding - Roche
 
Manon de Graaf
No Relationships to Disclose
 
Fabio Secomandi
No Relationships to Disclose
 
Matilde Cacciatore
No Relationships to Disclose
 
Andrea Botticelli
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche
 
Andrea Vingiani
Honoraria - Lilly; Roche
 
Giuseppe Fotia
No Relationships to Disclose
 
Gaia Griguolo
Consulting or Advisory Role - Gilead Sciences; Menarini; Seagen
Speakers' Bureau - Lilly; MSD
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Pfizer
 
Tommaso Giarratano
Honoraria - Gilead Sciences; Roche
Consulting or Advisory Role - Gilead Sciences; Roche
 
Valerio Pellegrini
No Relationships to Disclose
 
Daniela Iannaccone
No Relationships to Disclose
 
Francesca Porra
No Relationships to Disclose
 
Matteo Fassan
Consulting or Advisory Role - Amgen; Amgen; Astellas Pharma; AstraZeneca; GlaxoSmithKline; Incyte; Janssen; Lilly; MSD Oncology; Novartis; Pierre Fabre; Roche
Research Funding - Astellas Pharma; Diaceutics; Macrophage Pharma; QED Therapeutics
 
Giancarlo Pruneri
Honoraria - Foundation One Inc; Illumina; Lilly; Novartis
Consulting or Advisory Role - ADS Biotec; Incyte
 
Angelo Paolo Dei Tos
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; GlaxoSmithKline; Novartis; PharmaMar; Roche
 
Valentina Guarneri
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Lilly; Merck Serono; MSD; Novartis; Olema Oncology; Pierre Fabre
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Lilly; Menarini Steamline; Novartis; Roche; Zentiva
Research Funding - AstraZeneca (Inst); BMS (Inst); Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Synthon (Inst)
Expert Testimony - Lilly
Travel, Accommodations, Expenses - AstraZeneca; Gilead/Forty Seven
 
Marleen Kok
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo (Inst); Bristol-Myers Squibb/Medarex (Inst); Domain Therapeutics (Inst); MSD (Inst); Roche (Inst)
Speakers' Bureau - Gilead Sciences (Inst)
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Roche (Inst)
Other Relationship - Natera (Inst)
 
Maria Vittoria Dieci
Consulting or Advisory Role - Daiichi Sankyo; Exact Sciences; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
Patents, Royalties, Other Intellectual Property - Patent pending HER2DX licensed to University of Padova